作者: Chinmay S. Marathe , Christopher K. Rayner , Karen L. Jones , Michael Horowitz
DOI: 10.1155/2011/279530
关键词: Incretin 、 Gastrointestinal tract 、 Small intestine 、 Internal medicine 、 Endocrinology 、 Biology 、 Pharmacology 、 Glucagon-like peptide-1 、 Postprandial 、 Enterogastrone 、 Gastric acid 、 Enteral administration
摘要: Glucagon-like peptide 1 (GLP-1) is a hormone secreted predominantly by the distal small intestine and colon released in response to enteral nutrient exposure. GLP-1-based therapies are now used widely management of type 2 diabetes have potential be effective antiobesity agents. Although known as an incretin hormone, there growing body evidence that GLP-1 also acts enterogastrone, with profound effects on gastrointestinal motor system. Moreover, motility appear pivotal its effect reducing postprandial glycaemic excursions may, potentially, represent dominant mechanism. This review summarizes current knowledge enterogastrone properties GLP-1, focusing gut at physiological pharmacological concentrations, actions incretin-based therapies. While importance, inhibitory action gastric acid secretion beyond scope this paper.